Abstract
There has been growing interest among the public and scientists in dichloroacetate (DCA) as a potential anticancer drug. Credible evidence exists for the antitumor activity of this compound, but high concentrations are needed for significant therapeutic effect. Unfortunately, these high concentrations produce detrimental side effects involving the nervous system, thereby precluding its use for cancer treatment. The mechanistic basis of the compound's antitumor activity is its ability to activate the pyruvate dehydrogenase complex through inhibition of pyruvate dehydrogenase kinase. As the compound inhibits the kinase at micromolar concentrations, it is not known why therapeutically prohibitive high doses are needed for suppression of tumor growth. We hypothesized that lack of effective mechanisms for the entry of DCA into tumor cells may underlie this phenomenon. Here we show that SLC5A8 transports DCA very effectively with high affinity. This transporter is expressed in normal cells, but expression is silenced in tumor cells by epigenetic mechanisms. The lack of the transporter makes tumor cells resistant to the antitumor activity of DCA. However, if the transporter is expressed in tumor cells ectopically, the cells become sensitive to the drug at low concentrations. This is evident in breast cancer cells, colon cancer cells and prostate cancer cells. Normal cells, which constitutively express the transporter, are however not affected by the compound, indicating tumor cell-selective therapeutic activity. The mechanism of the compound's antitumor activity still remains its ability to inhibit pyruvate dehydrogenase kinase and force mitochondrial oxidation of pyruvate. As silencing of SLC5A8 in tumors involves DNA methylation and its expression can be induced by treatment with DNA methylation inhibitors, our findings suggest that combining DCA with a DNA methylation inhibitor would offer a means to reduce the doses of DCA to avoid detrimental effects associated with high doses but without compromising antitumor activity.
Similar content being viewed by others
References
Baylin SB . (2005). DNA methylation and gene silencing in cancer. Nat Clin Pract Oncol 2: S4–S11.
Bonnet S, Archer SL, Allalunis-Turner J, Haromy A, Beaulieu C, Thompson R et al. (2007). A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell 11: 37–51.
Brahimi-Horn MC, Chiche J, Pouyssegur J . (2007). Hypoxia signaling controls metabolic demand. Curr Opin Cell Biol 19: 223–229.
Brandsma D, Dorlo TP, Haanen JH, Beijnen JH, Boogerd W . (2010). Severe encephalopathy and polyneuropathy induced by dichloroacetate. J Neurol 257: 2099–2100.
Calcutt NA, Lopez VL, Bautista AD, Mizisin LM, Torres BR, Shroads AL et al. (2009). Peripheral neuropathy in rats exposed to dichloroacetate. J Neuropathol Exp Neurol 68: 985–993.
Cao W, Yacoub S, Shiverick KT, Namiki K, Sakai Y, Porvasnik S et al. (2008). Dichloroacetate (DCA) sensitizes both wild type and over expressing Bcl-2 prostate cancer cells in vitro to radiation. Prostate 68: 1223–1231.
Chen Z, Lu W, Garcia-Prieto C, Huang P . (2007). The Warburg effect and its cancer therapeutic implications. J Bioenerg Biomembr 39: 267–274.
Coady MJ, Chang MH, Charron FM, Plata C, Wallendorff B, Sah JF et al. (2004). The tumour suppressor gene SLC5A8 expresses a Na+-monocarboxylate cotransporter. J Physiol 557: 719–731.
Cooper RH, Randle PJ, Denton RM . (1974). Regulation of heart muscle pyruvate dehydrogenase kinase. Biochem J 143: 625–641.
Ganapathy V, Gopal E, Miyauchi S, Prasad PD . (2005). Biological functions of SLC5A8, a candidate tumor suppressor. Biochem Soc Trans 33: 237–240.
Ganapathy V, Thangaraju M, Gopal E, Itagaki S, Miyauchi S, Prasad PD . (2008). Sodium-coupled monocarboxylate transporters in normal tissues and in cancer. AAPS J 10: 193–199.
Ganapathy V, Thangaraju M, Prasad PD . (2009). Nutrient transporters in cancer: relevance to Warburg hypothesis and beyond. Pharmacol Ther 121: 29–40.
Gatenby RA, Gillies RJ . (2004). Why do cancers have high aerobic glycolysis? Nat Rev Cancer 4: 891–899.
Gopal E, Fei YJ, Miyauchi S, Zhuang L, Prasad PD, Ganapathy V . (2005). Sodium-coupled and electrogenic transport of B-complex vitamin nicotinic acid by Slc5a8, a member of the Na+/glucose cotransporter gene family. Biochem J 388: 309–316.
Gopal E, Fei YJ, Sugawara M, Miyauchi S, Zhuang L, Martin PM et al. (2004). Expression of Slc5a8 in kidney and its role in Na+-coupled transport of lactate. J Biol Chem 279: 44522–44532.
Gupta N, Martin PM, Prasad PD, Ganapathy V . (2006). SLC5A8 (SMCT1)-mediated transport of butyrate forms the basis for the tumor suppressive function of the transporter. Life Sci 78: 2419–2425.
Heshe D, Hoogestraat S, Brauckmann C, Karst U, Boos J, Lanvers-Kaminsky C . (2010). Dichloroacetate metabolically targeted therapy defeats cytotoxicity of standard anticancer drugs. Cancer Chemother Pharmacol 67: 647–655.
Hong C, Maunakea A, Jun P, Bollen AW, Hodgson JG, Goldenberg DD et al. (2005). Shared epigenetic mechanisms in human and mouse gliomas inactivate expression of the growth suppressor SLC5A8. Cancer Res 65: 3617–3623.
Jackson VN, Halestrap AP . (1996). The kinetics, substrate, and inhibitor specificity of the monocarboxylate (lactate) transporter of rat liver cells determined using the fluorescent intracellular pH indicator, 2′,7′-bis (carboxyethyl)-5(6)-carboxyfluorescein. J Biol Chem 271: 861–868.
Kim JW, Dang CV . (2006). Cancer's molecular sweet tooth and the Warburg effect. Cancer Res 66: 8927–8930.
Li H, Myeroff L, Smiraglia D, Romero MF, Pretlow TP, Kasturi L et al. (2003). SLC5A8, a sodium transporter, is a tumor suppressor gene silenced by methylation in human colon aberrant crypt foci and cancers. Proc Natl Acad Sci USA 100: 8412–8417.
Madhok BM, Yeluri S, Perry SL, Hughes TA, Jayne DG . (2010). Dichloroacetate induces apoptosis and cell-cycle arrest in colorectal cancer cells. Br J Cancer 102: 1746–1752.
Martin PM, Gopal E, Ananth S, Zhuang L, Itagaki S, Prasad BM et al. (2006). Identity of SMCT1 (SLC5A8) as a neuron-specific Na+-coupled transporter for active uptake of L-lactate and ketone bodies in the brain. J Neurochem 98: 279–288.
Mathupala SP, KO YH, Pedersen PL . (2010). The pivotal roles of mitochondria in cancer: Warburg and beyond and encouraging prospects for effective therapies. Biochim Biophys Acta 1797: 1225–1230.
Michelakis ED, Sutendra G, Dromparis P, Webster L, Haromy A, Niven E et al. (2010). Metabolic modulation of glioblastoma with dichloroacetate. Sci Transl Med 2: 31–34.
Michelakis ED, Webster L, Mackey JR . (2008). Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer. Br J Cancer 99: 989–994.
Miyauchi S, Gopal E, Babu E, Sonne SR, Kubo Y, Umapathy NS et al. (2010). Sodium-coupled electrogenic transport of pyroglutamate (5-oxoproline) via SLC5A8, a monocarboxylate transporter. Biochim Biophys Acta 1798: 1164–1171.
Miyauchi S, Gopal E, Fei YJ, Ganapathy V . (2004). Functional identification of SLC5A8, a tumor suppressor downregulated in colon cancer, as a Na+-coupled transporter for short-chain fatty acids. J Biol Chem 279: 13293–13296.
Park JY, Helm JF, Zheng W, Ly QP, Hodul PJ, Centeno BA et al. (2008). Silencing of the candidate tumor suppressor gene solute carrier family 5 member 8 (SLC5A8) in human pancreatic cancer. Pancreas 36: e32–e39.
Park JY, Zheng W, Kim D, Cheng JQ, Kumar N, Ahmad N et al. (2007). Candidate tumor suppressor gene SLC5A8 is frequently downregulated by promoter hypermethylation in prostate cancer. Cancer Detect Prev 31: 359–365.
Pearson H . (2007). Cancer patients opt for unapproved drug. Nature 446: 474–475.
Porra V, Ferraro-Peyret C, Durand C, Selmi-Ruby S, Giroud H, Berger-Dutrieux N et al. (2005). Silencing of the tumor suppressor gene SLC5A8 is associated with BRAF mutations is classical papillary thyroid carcinomas. J Clin Endocrinol Metab 90: 3028–3035.
Semenza GL . (2010). HIF-1: upstream and downstream of cancer metabolism. Curr Opin Genet Dev 20: 51–56.
Stacpoole PW, Henderson GN, Yan Z, Cornett R, James MO . (1998). Pharmacokinetics, metabolism and toxicology of dichloroacetate. Drug Metab Rev 30: 499–539.
Stacpoole PW, Kurtz TL, Han Z, Langaee T . (2008). Role of dichloroacetate in the treatment of genetic mitochondrial diseases. Adv Drug Deliv Rev 60: 1478–1487.
Stacpoole PW, Nagaraja NV, Hutson AD . (2003). Efficacy of dichloroacetate as a lactate-lowering drug. J Clin Pharmacol 43: 683–691.
Stockwin LH, Yu SX, Borgel S, Hancock C, Wolfe TL, Phillips LR et al. (2010). Sodium dichloroacetate (DCA) selectively targets cells with defects in the mitochondrial ETC. Int J Cancer 127: 2510–2519.
Sun RC, Fadia M, Dahlstrom JE, Parish CR, Board PG, Blackburn AC . (2010). Reversal of the glycolytic phenotype by dichloroacetate inhibits metastatic breast cancer cell growth in vitro and in vivo. Breast Cancer Res Treat 120: 253–260.
Thangaraju M, Carswell KN, Prasad PD, Ganapathy V . (2009b). Colon cancer cells maintain low levels of pyruvate to avoid cell death caused by inhibition of HDAC1/HDAC3. Biochem J 417: 379–389.
Thangaraju M, Cresci G, Itagaki S, Mellinger J, Browning DD, Berger FG et al. (2008). Sodium-coupled transport of the short-chain fatty acid butyrate by SLC5A8 and its relevance to colon cancer. J Gastrointest Surg 12: 1773–1782.
Thangaraju M, Gopal E, Martin PM, Ananth S, Smith SB, Prasad PD et al. (2006). SLC5A8 triggers tumor cell apoptosis through pyruvate-dependent inhibition of histone deacetylases. Cancer Res 66: 11560–11564.
Thangaraju M, Karunakaran S, Itagaki S, Gopal E, Elangovan S, Prasad PD et al. (2009a). Transport via SLC5A8 with subsequent inhibition of histone deacetylases HDAC1 and HDAC3 underlies the antitumor activity of 3-bromopyruvate. Cancer 115: 4655–4666.
Ueno M, Toyota M, Akino K, Suzuki H, Kusano M, Satoh A et al. (2004). Aberrant methylation and histone deacetylation associated with silencing of SLC5A8 in gastric cancer. Tumour Biol 25: 134–140.
Vander Heiden MG, Cantley LC, Thompson CB . (2009). Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324: 1029–1033.
Warburg O . (1956). On the origin of cancer cells. Science 123: 309–314.
Weimer LH, Sachdev N . (2009). Update on medication-induced peripheral neuropathy. Curr Neurol Neurosci Rep 9: 69–75.
Whitehouse S, Cooper RH, Randle PJ . (1974). Mechanism of activation of pyruvate dehydrogenase by dichloroacetate and other halogenated carboxylic acids. Biochem J 141: 761–774.
Wong JY, Huggins GS, Debidda M, Munshi NC, De Vivo I . (2008). Dichloroacetate induces apoptosis in endometrial cancer cells. Gynecol Oncol 109: 394–402.
Xiao L, Li X, Niu N, Qian J, Xie G, Wang Y . (2010). Dichloroacetate (DCA) enhances tumor cell death in combination with oncolytic adenovirus armed with MDA-7/IL-24. Mol Cell Biochem 340: 31–40.
Acknowledgements
The work described here is supported in part by the National Institutes of Health Grant CA131402.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Babu, E., Ramachandran, S., CoothanKandaswamy, V. et al. Role of SLC5A8, a plasma membrane transporter and a tumor suppressor, in the antitumor activity of dichloroacetate. Oncogene 30, 4026–4037 (2011). https://doi.org/10.1038/onc.2011.113
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2011.113
- Springer Nature Limited
Keywords
This article is cited by
-
Perillyl alcohol and its synthetic derivatives: the rising of a novel class of selective and potent antitumoral compounds
Medicinal Chemistry Research (2022)
-
Effects of adding sodium dichloroacetate to low-protein diets on nitrogen balance and amino acid metabolism in the portal-drained viscera and liver of pigs
Journal of Animal Science and Biotechnology (2020)
-
Dichloroacetate and Salinomycin Exert a Synergistic Cytotoxic Effect in Colorectal Cancer Cell Lines
Scientific Reports (2018)
-
Dichloroacetate affects proliferation but not survival of human colorectal cancer cells
Apoptosis (2015)
-
Anticancer activity of structurally related ruthenium(II) cyclopentadienyl complexes
JBIC Journal of Biological Inorganic Chemistry (2014)